F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational healthcare giant headquartered in Basel, Switzerland. Founded in 1896 by Fritz Hoffmann-La Roche, it is one of the world’s largest pharmaceutical companies and the global leader in cancer treatments and in-vitro diagnostics.
Roche headquarters in Basel, Switzerland. Bron: Rafael_Wiedenmeier / Getty Images
Core Business Divisions
Roche operates under two primary global divisions:
- Pharmaceuticals: Focuses heavily on biotechnology, oncology, immunology, ophthalmology, infectious diseases, and neuroscience. Major blockbusters include Ocrevus (multiple sclerosis), Hemlibra (hemophilia A), Tecentriq (cancer immunotherapy), and historical oncology anchors Herceptin, Avastin, and Rituxan.
- Diagnostics: Develops diagnostic instruments, assays, and digital solutions for hospitals, laboratories, and point-of-care testing. It is a market leader in molecular diagnostics, tissue pathology, and blood glucose monitoring (Accu-Chek).
Strategic Milestones & Structure
- Genentech Acquisition: Roche acquired full ownership of US biotech pioneer Genentech in 2009 for $46.8 billion, making Genentech its primary US research hub and core engine for biological medicines.
- Personalized Healthcare: Roche pioneered the combination of in-house diagnostic tools with targeted therapeutics, enabling healthcare providers to match treatments to patients‘ specific genetic profiles.
- Ownership: The founding Hoffmann-Oeri family holds the controlling pool of voting bearer shares, maintaining long-term independence while non-voting equity shares (Genusstscheine) trade publicly on the SIX Swiss Exchange.
Did the genusstscheine of Roche improve in value over the last 5 years>
To evaluate the 5-year performance of Roche’s non-voting equity certificates (Genussscheine, ticker: ROG), it helps to distinguish between capital appreciation (share price movement) and total return (price appreciation plus reinvested dividends).
1. Capital Appreciation (Price Movement)
On a pure share price basis, Roche Genussscheine did not gain value compared to five years ago, though they have recovered significantly from their multi-year lows.
- 5 Years Ago (Mid-2021): Trading around CHF 350 – CHF 360.
- Peak (Spring 2022): Reached an all-time high of over CHF 400 driven by COVID-19 diagnostics demand and pharmaceutical revenues.
- Bottom (Early 2024): Dropped to around CHF 220 – CHF 245 due to the steep decline in post-pandemic COVID testing revenue, clinical trial setbacks, and Swiss franc strength.
- Current Level (2026): Rebounded back to around CHF 330 – CHF 358.
Verdict on Nominal Price: The price is slightly below or roughly flat relative to 2021 levels (a modest loss to flat performance depending on the exact buying window in 2021).
2. Total Shareholder Return (TSR)
If you include dividend payouts, the investment yielded a positive total return:
- Roche is a reliable dividend growth stock, having increased its payout for 38+ consecutive years.
- Over the past 5 years, Roche paid out substantial cumulative dividends per non-voting certificate:
- 2021: CHF 9.30
- 2022: CHF 9.50
- 2023: CHF 9.60
- 2024: CHF 9.70
- 2025: CHF 9.80
- Summing these cash payouts yields over CHF 47 per Genussschein in cash dividends alone over the 5-year holding period.
Summary
- Price alone: Virtually flat to slightly down compared to 2021 levels.
- Total Return (Price + Dividends): Improved in value thanks to a steady annual dividend yield of ~3–4%.